RET inhibitor

Last updated

RET inhibitors are targeted therapies that act on tumors with activating alterations in the RET proto-oncogene, such as point mutations or fusions. They fall under the category of the tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of cancer cells. Existing molecules fall in two main categories: the older multikinase inhibitors and the more recent selective inhibitors. Although RET alterations are found at low frequency in a broad range of tumors, the three main indications for RET inhibitors today are non-small cell lung cancer (which harbor RET fusions at a frequency of 1-2%), medullary thyroid cancer (MTC, with activating RET mutations in 25% of cases) and papillary thyroid cancer (PTC, with up to 80% prevalence of fusions depending on the region). As of 2020, up to 48 fusion partners have been catalogued in NSCLC rearrangements, with KIF5B and CCDC6 being the most prevalent. [1] At least 10 different fusion variants have been described for KIF5B-RET, each with different breakpoints within the partner gene, but unclear clinical impact as of 2018. [2]

Contents

Multikinase inhibitors

Cabozantinib, a multikinase inhibitor targeting c-MET, VEGFR2, AXL and RET Cabozantinib.svg
Cabozantinib, a multikinase inhibitor targeting c-MET, VEGFR2, AXL and RET

Multikinase inhibitors are molecules that possess a broad range of targets along with RET. These included cabozantinib, lenvatinib, sunitinib and alectinib. Since they were not designed to bind RET specifically, these inhibitors have other targets such as VEGFR, c-MET, and c-KIT. Among them, the VEGFR-related toxicities commonly precluded patients from achieving therapeutic doses with these medications, resulting in incomplete inhibition of RET and suboptimal clinical outcomes. In NSCLC, overall response rates (ORR) were low (16% for lenvatinib, [3] 28% for cabozantinib [4] ), and progression-free survival (PFS) hovered around 6 months with a very high percentage of patients requiring dose reductions or discontinuing treatment (73% of patients on cabozantinib). Resistance to these medications included on-target mutations on the V804 gatekeeper residue, [5] as well as off-target mechanisms such as EGFR pathway activation and MDM2 amplifications. [6] Differences in efficacy also arose depending on the fusion partner, with non-KIF5B fusions typically responding better to these multikinase inhibitors than KIF5B-RET-driven tumors.

Compared to the much higher response rates and longer progression-free survivals achieved by selective inhibitors in other kinase fusions such as ALK or ROS1, these molecules offered much more limited clinical benefit, which highlighted a critical need for highly selective RET inhibitors.

Selective RET inhibitors

Pralsetinib, a selective inhibitor of RET with activity against JAK2 Pralsetinib.svg
Pralsetinib, a selective inhibitor of RET with activity against JAK2

Around 2017, the first selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) started their first phase I/II clinical trials in solid tumors. They were designed to have high potency for RET, along with low affinity for other related targets such as VEGFR-family kinases to limit off-target toxicities. They were also designed to overcome the V804 gatekeeper mutations that some patients acquired under multikinase inhibitors. In patients who had previously received platinum chemotherapies for their lung cancers, ORRs hovered around 60% with median PFS between 17 months and not-evaluable (NE). [7] [8] Similar promising results came out for thyroid cancers as well, with response rates at 70-80% and median PFS between 18 and 22 months. [9] The encouraging results of the phase I/II trials led to the FDA approvals of selpercatinib (Retevmo™) for RET-driven NSCLC, MTC and PTC in May 2020, and the approval of pralsetinib (Gavreto™) for RET-fusion NSCLC in September 2020, as well as MTC and PTC in December 2020.

Resistance mechanisms to this first generation of selective RET inhibitors include different on-target mutations on the G810 solvent-front residue, [10] as well as off-target alterations such as MET amplifications and KRAS mutations among others. TP53 mutational status appears to have an impact on prognosis and resistance mechanisms, with TP53-mutated tumors showing shorter PFS and mostly off-target resistance mechanisms. [11]

Investigational therapies

Single-compounds

Several other molecules are currently being investigated as selective RET inhibitors. Boston Therapeutics' BOS172738 seemingly falls in the same category as the approved first-generation inhibitors, with selectivity against VEGFR2, similar clinical activity, and susceptibility to the G810 resistance mutation. [12] Turning Point Therapeutics' TPX-0046 is a compound that is claimed to target the G810 mutation, as well as Src family kinases, but is susceptible to the gatekeeper V804 mutation. [13] Other compounds include Helsinn's HM06, which presented data in October 2021 showing significant activity against both the G810 and V804 mutations individually, making it a brain-penetrant second-generation RET inhibitor for which a clinical trial is open in the US since February 2021.

In 2021, Eli Lilly announced preclinical results for LOX-18228 and LOX-19260, two next-generation RET inhibitor candidates capable of tackling the G810 and V804 mutations individually as well as in tandem (G810+V804). The study looked at cell lines and mouse models with KIF5B-RET and CCDC6-RET fusions, as well as lines with the M918T mutation. The compounds showed strong selectivity and efficacy across cells lines. The company renamed one of these candidates LOXO-260, for which a Phase I clinical trial is expected in Q1 2022. [14]

Combinations

While selective inhibitors are not yet (as of 2021) being evaluated in combination with other compounds to treat therapy-naïve patients, they are still being investigated to treat RET fusions arising as resistance mechanisms to other treatments. Notably, around 5% of EGFR-mutated non-small-cell lung cancers develop RET fusions as a resistance mechanism to the third-generation EGFR inhibitor osimertinib. [15] For these patients, the combination of osimertinib and selpercatinib is currently being evaluated in a cohort of the ORCHARD study. [16]

Discontinued compounds

Among older compounds being investigated for RET inhibition, RXDX-105 was being developed by Ignyta as a VEGF-sparing multikinase inhibitor of BRAF, RET and EGFR. It was discontinued after acquisition of the company by Hoffmann-La Roche, citing a poor efficacy profile compared to the selective inhibitors being developed parallel to it. While it boasted a 75% response rate among fusions with non-KIF5B partners (6 out of 8 patients), there were no responses for patients with the KIF5B fusion partner (0 out of 20 patients), which represents more than 65% of RET fusions in NSCLC. [17] Among cited reasons for this difference is the KIF5B promoter inducing higher expression of the KIF5B-RET fusion protein compared to other partners, which would result in incomplete inhibition at clinical doses of RXDX-105 and reduced therapeutic activity.

Diagnostics

In order to identify patients most likely to benefit from RET inhibitors, several companion diagnostic assays are approved. Regardless of the alteration, tissue-based NGS remains the gold standard with very high specificity and sensitivity. In the case of rearrangements, RT-PCR is a proven technique with high specificity and sensitivity, but it will miss fusions with rare partners. FISH can be used where other techniques are not available, but the relative subjectivity of the test along with the proximity of common partners to the RET gene can make it difficult to discern rearrangements. Plasma-based NGS assays are becoming more and more prevalent because of their ease of use and high specificity, although they are limited by how much circulating tumor DNA is present in the sample, which itself depends upon how much DNA the tumors shed into the blood. This means that while a positive result may be taken as certainty, a negative result might simply mean not enough material was collected, and should be confirmed with another technique to rule out a false-negative.

Related Research Articles

<span class="mw-page-title-main">Gefitinib</span> Drug used in fighting breast, lung, and other cancers

Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, but resistances to gefitinib can arise through other mutations. It is marketed by AstraZeneca and Teva.

<span class="mw-page-title-main">Erlotinib</span> EGFR inhibitor for treatment of non-small-cell lung cancer

Erlotinib, sold under the brand name Tarceva among others, is a medication used to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. Specifically it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) — either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation — which has spread to other parts of the body. It is taken by mouth.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Non-small-cell lung cancer</span> Any type of epithelial lung cancer other than small-cell lung carcinoma

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

<span class="mw-page-title-main">Fibroblast growth factor receptor 1</span> Protein-coding gene in the species Homo sapiens

Fibroblast growth factor receptor 1 (FGFR1), also known as basic fibroblast growth factor receptor 1, fms-related tyrosine kinase-2 / Pfeiffer syndrome, and CD331, is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. FGFR1 has been shown to be associated with Pfeiffer syndrome, and clonal eosinophilias.

<span class="mw-page-title-main">ROS1</span> Protein-coding gene in the species Homo sapiens

Proto-oncogene tyrosine-protein kinase ROS is an enzyme that in humans is encoded by the ROS1 gene.

<span class="mw-page-title-main">Afatinib</span> Chemical compound

Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.

<span class="mw-page-title-main">Adenocarcinoma of the lung</span> Medical condition

Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis. Lung adenocarcinoma is further classified into several subtypes and variants. The signs and symptoms of this specific type of lung cancer are similar to other forms of lung cancer, and patients most commonly complain of persistent cough and shortness of breath.

<span class="mw-page-title-main">Crizotinib</span> ALK inhibitor for treatment of non-small-cell lung cancer

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). It acts as an ALK and ROS1 inhibitor.

<span class="mw-page-title-main">ALK inhibitor</span>

ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion, although as of 2020, over 92 fusion partners have been discovered in ALK+ NSCLC. For each fusion partner, there can be several fusion variants depending on the position the two genes were fused at, and this may have implications on the response of the tumour and prognosis of the patient.

Angiokinase inhibitors are a new therapeutic target for the management of cancer. They inhibit tumour angiogenesis, one of the key processes leading to invasion and metastasis of solid tumours, by targeting receptor tyrosine kinases. Examples include nintedanib, afatinib and motesanib.

A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2. They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers.

Growth factor receptor inhibitors are drugs that target the growth factor receptors of cells. They interfere with binding of the growth factor to the corresponding growth factor receptors, impeding cell growth and are used medically to treat cancer.

<span class="mw-page-title-main">Binimetinib</span> Chemical compound

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma.

<span class="mw-page-title-main">Osimertinib</span> Chemical compound, used as a medication to treat lung cancer

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

<span class="mw-page-title-main">Entrectinib</span> TKI inhibitor used for cancer treatment

Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).

<span class="mw-page-title-main">Selpercatinib</span> Chemical compound

Selpercatinib, sold under the brand name Retevmo among others, is a medication for the treatment of cancers in people whose tumors have an alteration in a specific gene. It is taken by mouth.

Pralsetinib, sold under the brand name Gavreto, is a medication approved for RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy. Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.

References

  1. ↑ Ou, Sai-Hong Ignatius; Zhu, Viola W. (2020). "Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020". JTO Clinical and Research Reports. 1 (2): 100037. doi: 10.1016/j.jtocrr.2020.100037 . ISSN   2666-3643. PMC   8474217 . PMID   34589933.
  2. ↑ Ferrara, Roberto; Auger, Nathalie; Auclin, Edouard; Besse, Benjamin (2018). "Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer". Journal of Thoracic Oncology. 13 (1): 27–45. doi: 10.1016/j.jtho.2017.10.021 . ISSN   1556-0864. PMID   29128428.
  3. ↑ Hida, Toyoaki; Velcheti, Vamsidhar; Reckamp, Karen L.; Nokihara, Hiroshi; Sachdev, Pallavi; Kubota, Tomoki; Nakada, Takuya; Dutcus, Corina E.; Ren, Min; Tamura, Tomohide (2019). "A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma". Lung Cancer. 138: 124–130. doi: 10.1016/j.lungcan.2019.09.011 . ISSN   0169-5002. PMID   31710864.
  4. ↑ Drilon, Alexander; Rekhtman, Natasha; Arcila, Maria; Wang, Lu; Ni, Andy; Albano, Melanie; Van Voorthuysen, Martine; Somwar, Romel; Smith, Roger S; Montecalvo, Joseph; Plodkowski, Andrew; Ginsberg, Michelle S; Riely, Gregory J; Rudin, Charles M; Ladanyi, Marc; Kris, Mark G (2016). "Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial". The Lancet Oncology. 17 (12): 1653–1660. doi:10.1016/S1470-2045(16)30562-9. ISSN   1470-2045. PMC   5143197 . PMID   27825636.
  5. ↑ Wirth, Lori J.; Kohno, Takashi; Udagawa, Hibiki; Matsumoto, Shingo; Ishii, Genichiro; Ebata, Kevin; Tuch, Brian B.; Zhu, Edward Y.; Nguyen, Michele; Smith, Steve; Hanson, Lauren M.; Burkard, Michael R.; Cable, LouAnn; Blake, James F.; Condroski, Kevin R.; Brandhuber, Barbara J.; Andrews, Steve; Rothenberg, S. Michael; Goto, Koichi (2019). "Emergence and Targeting of Acquired and Hereditary Resistance to Multikinase RET Inhibition in Patients With RET-Altered Cancer". JCO Precision Oncology. 3 (3): 1–7. doi:10.1200/PO.19.00189. ISSN   2473-4284. PMC   7446343 . PMID   32923848.
  6. ↑ Bronte, Giuseppe; Ulivi, Paola; Verlicchi, Alberto; Cravero, Paola; Delmonte, Angelo; Crinò, Lucio (2019). "

    Targeting RET-rearranged non-small-cell lung cancer: future prospects

    "    . Lung Cancer: Targets and Therapy. 10: 27–36. doi: 10.2147/LCTT.S192830 . ISSN   1179-2728. PMC   6433115 . PMID   30962732. S2CID   102347736.
  7. ↑ Drilon, Alexander; Oxnard, Geoffrey R.; Tan, Daniel S.W.; Loong, Herbert H.F.; Johnson, Melissa; Gainor, Justin; McCoach, Caroline E.; Gautschi, Oliver; Besse, Benjamin; Cho, Byoung C.; Peled, Nir; Weiss, Jared; Kim, Yu-Jung; Ohe, Yuichiro; Nishio, Makoto; Park, Keunchil; Patel, Jyoti; Seto, Takashi; Sakamoto, Tomohiro; Rosen, Ezra; Shah, Manisha H.; Barlesi, Fabrice; Cassier, Philippe A.; Bazhenova, Lyudmila; De Braud, Filippo; Garralda, Elena; Velcheti, Vamsidhar; Satouchi, Miyako; Ohashi, Kadoaki; Pennell, Nathan A.; Reckamp, Karen L.; Dy, Grace K.; Wolf, Jürgen; Solomon, Benjamin; Falchook, Gerald; Ebata, Kevin; Nguyen, Michele; Nair, Binoj; Zhu, Edward Y.; Yang, Luxi; Huang, Xin; Olek, Elizabeth; Rothenberg, S. Michael; Goto, Koichi; Subbiah, Vivek (2020). "Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer". New England Journal of Medicine. 383 (9): 813–824. doi:10.1056/NEJMoa2005653. ISSN   0028-4793. PMC   7506467 . PMID   32846060.
  8. ↑ FDA (9 September 2020). "FDA approves pralsetinib for lung cancer with RET gene fusions". fda.gov. Retrieved 15 October 2020.
  9. ↑ Wirth, Lori J.; Sherman, Eric; Robinson, Bruce; Solomon, Benjamin; Kang, Hyunseok; Lorch, Jochen; Worden, Francis; Brose, Marcia; Patel, Jyoti; Leboulleux, Sophie; Godbert, Yann; Barlesi, Fabrice; Morris, John C.; Owonikoko, Taofeek K.; Tan, Daniel S.W.; Gautschi, Oliver; Weiss, Jared; de la Fouchardière, Christelle; Burkard, Mark E.; Laskin, Janessa; Taylor, Matthew H.; Kroiss, Matthias; Medioni, Jacques; Goldman, Jonathan W.; Bauer, Todd M.; Levy, Benjamin; Zhu, Viola W.; Lakhani, Nehal; Moreno, Victor; Ebata, Kevin; Nguyen, Michele; Heirich, Dana; Zhu, Edward Y.; Huang, Xin; Yang, Luxi; Kherani, Jennifer; Rothenberg, S. Michael; Drilon, Alexander; Subbiah, Vivek; Shah, Manisha H.; Cabanillas, Maria E. (2020). "Efficacy of Selpercatinib in RET-Altered Thyroid Cancers". New England Journal of Medicine. 383 (9): 825–835. doi: 10.1056/NEJMoa2005651 . ISSN   0028-4793. PMC   10777663 . PMID   32846061.
  10. ↑ Solomon, Benjamin J.; Tan, Lavinia; Lin, Jessica J.; Wong, Stephen Q.; Hollizeck, Sebastian; Ebata, Kevin; Tuch, Brian B.; Yoda, Satoshi; Gainor, Justin F.; Sequist, Lecia V.; Oxnard, Geoffrey R.; Gautschi, Oliver; Drilon, Alexander; Subbiah, Vivek; Khoo, Christine; Zhu, Edward Y.; Nguyen, Michele; Henry, Dahlia; Condroski, Kevin R.; Kolakowski, Gabrielle R.; Gomez, Eliana; Ballard, Joshua; Metcalf, Andrew T.; Blake, James F.; Dawson, Sarah-Jane; Blosser, Wayne; Stancato, Louis F.; Brandhuber, Barbara J.; Andrews, Steve; Robinson, Bruce G.; Rothenberg, S. Michael (2020). "RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies". Journal of Thoracic Oncology. 15 (4): 541–549. doi:10.1016/j.jtho.2020.01.006. ISSN   1556-0864. PMC   7430178 . PMID   31988000.
  11. ↑ Lin, J.J.; Liu, S.V.; McCoach, C.E.; Zhu, V.W.; Tan, A.C.; Yoda, S.; Peterson, J.; Do, A.; Prutisto-Chang, K.; Dagogo-Jack, I.; Sequist, L.V.; Wirth, L.J.; Lennerz, J.K.; Hata, A.N.; Mino-Kenudson, M.; Nardi, V.; Ou, S.-H.I.; Tan, D.S.-W.; Gainor, J.F. (2020). "Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer". Annals of Oncology. 31 (12): 1725–1733. doi: 10.1016/j.annonc.2020.09.015 . ISSN   0923-7534. PMC   9538591 . PMID   33007380.
  12. ↑ Schoffski, Patrick; Cho, Byoung Chul; Italiano, Antoine; Loong, Herbert H. F.; Massard, Christophe; Medina Rodriguez, Laura; Shih, Jin-Yuan; Subbiah, Vivek; Verlingue, Loic; Andreas, Karen; Basson, Craig T.; Clawson, Alicia; Ho, Peter T.C.; Knight, Shelley; Scheuber, Anita; Keegan, Mitchell (2021-05-20). "BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results". Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). 39 (15_suppl): 3008. doi:10.1200/jco.2021.39.15_suppl.3008. ISSN   0732-183X. S2CID   236336165.
  13. ↑ A. Drilon. "TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers" (PDF). tptherapeutics.com. Retrieved 15 October 2020.
  14. ↑ Kolakowski, Gabrielle R. (10 April 2021). "Pre-clinical characterization of potent and selective next-generation RET inhibitors". Aacr 2021 (Session PO.ET06.07). Retrieved 14 March 2021.
  15. ↑ Rich, Thereasa A.; Reckamp, Karen L.; Chae, Young Kwang; Doebele, Robert C.; Iams, Wade T.; Oh, Michael; Raymond, Victoria M.; Lanman, Richard B.; Riess, Jonathan W.; Stinchcombe, Thomas E.; Subbiah, Vivek; Trevarthen, David R.; Fairclough, Stephen; Yen, Jennifer; Gautschi, Oliver (2019). "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations". Clinical Cancer Research. 25 (19): 5832–5842. doi: 10.1158/1078-0432.CCR-18-4049 . ISSN   1078-0432. PMC   6774853 . PMID   31300450. S2CID   196349232.
  16. ↑ "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 20 October 2020.
  17. ↑ Drilon, Alexander; Fu, Siqing; Patel, Manish R.; Fakih, Marwan; Wang, Ding; Olszanski, Anthony J.; Morgensztern, Daniel; Liu, Stephen V.; Cho, Byoung Chul; Bazhenova, Lyudmila; Rodriguez, Cristina P.; Doebele, Robert C.; Wozniak, Antoinette; Reckamp, Karen L.; Seery, Tara; Nikolinakos, Petros; Hu, Zheyi; Oliver, Jennifer W.; Trone, Denise; McArthur, Katherine; Patel, Rupal; Multani, Pratik S.; Ahn, Myung-Ju (2019). "A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105". Cancer Discovery. 9 (3): 384–395. doi: 10.1158/2159-8290.CD-18-0839 . ISSN   2159-8274. PMC   6397691 . PMID   30487236.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.